Transforming DCB Strategy: Sirolimus-Coated Balloon With Nanolute Technology (Sponsored by Concept Medical, Inc.)

 


Please continue watching the satellites programs presented at TCT 2019:

Ability to Treat Diabetic Patients

 

Future and Scope

 

CHAIRPERSONS
 

Medtronic: The Foundations of TAVR

Martin B. Leon, MD
Columbia University Irving Medical Center
New York, NY

Transforming DCB Strategy: Sirolimus-Coated Balloon With Nanolute Technology (Sponsored by Concept Medical, Inc.) Shigeru Saito, MD
Shonan Kamakura General Hospital
Osaka, Japan

 

 

FACULTY
 

Aloke Finn, MD
C V Path
Gaithersburg, MD
Bernardo Cortese, MD
San Carlo Clinic
Milano, Italy
Sandeep Basavarajaiah
The University of Birmingham
Birmingham, UK
 
Ajay J. Kirtane, MD, SM, FACC, FSCAI
Columbia University Medical Center
New York, NY
Alexandre Abizaid, MD, PhD
Instituto Dante Pazzanese de Cardiologia
São Paulo, Brazil
Ori Ben-Yehuda, MD 
Cardiovascular Research Foundation
New York, NY

Azeem Latib
Montefiore Medical Center / Albert 
Einstein College of Medicine
New York, NY


AGENDA


Concept of Magic Touch
Presenter: Ajay Kirtane

Why SEB should be safer? Insights from pre-clinical study
Presenter: Aloke Finn

First In Man – Brazil ISR experience with angiographic and IVUS results
Presenter: Alexandre Abizaid

Magic touch Real World Experience

Realworld data from EASTBOURNE to TRANSFORM Trials
Presenter: Bernardo Cortese

Use of Sirolimus Coated Balloon (MagicTouch) in Coronary Intervention; Data and case examples from real world population
Presenter: Sandeep Basavarajaiah

FDA Pivotal Clinical Trial Design and Beyond
Presenter: Ori Ben-Yehuda

Panel Discussion and audience interaction (led by Dr. Martin Leon and Dr. Shigeru Saito)
Discussants: Alexandre Abizaid, Ajay Kirtane, Azeem Latib
 


 

Transforming DCB Strategy: Sirolimus-coated Balloon With Nanolute Technology

 

 This program was supported by: 

 

Concept Medical - Ability to Treat Diabetic Patients: With a Novel Combined DES and DCB in a Single Platform

Ability to Treat Diabetic Patients: With a Novel Combined DES + DCB in a Single Platform Ability to Treat Diabetic Patients: With a Novel Combined DES + DCB in a Single Platform Ability to Treat Diabetic Patients: With a Novel Combined DES + DCB in a Single Platform Ability to Treat Diabetic Patients: With a Novel Combined DES + DCB in a Single Platform